# Alvotech SDB > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/alvotechsdb). ## Overview Alvotech SDB is the Swedish depositary receipt of Alvotech, an Iceland-based biopharmaceutical company focused on developing and manufacturing biosimilar medicines. The business combines biosimilar product development, commercial supply, and out-licensing arrangements with partners that market the products in defined territories worldwide. ## Products & services • Biosimilar medicines development • Commercial supply of biosimilar products • Out-license and territory partnership agreements • Regulatory and clinical development services • Biosimilar product commercialization support - **Biosimilar product development** (35%) — Development of biosimilar candidates designed to match reference biologics. - **Product sales** (25%) — Sales of approved biosimilar products supplied to commercial partners or market channels. - **Out-licensing and milestones** (30%) — Territory-based licensing arrangements with upfront, milestone, and commercialization rights. - **Development services** (10%) — Partnered development work tied to licensed biosimilar compounds. - Biosimilar medicines development - Commercial supply of biosimilar products - Out-license and territory partnership agreements - Regulatory and clinical development services - Biosimilar product commercialization support ## Customers Alvotech sells primarily to commercial partners and licensees, not directly to end patients. These partners acquire territorial rights, development support, and supply agreements so they can register, market, and distribute biosimilar products in their own markets. The business also serves partners that buy finished product supply after approval and commercialization. - **Commercial partners and licensees** (primary) — Buy territorial rights, development support, and supply agreements so they can commercialize biosimilars in their markets. - **Product supply customers** (primary) — Purchase approved biosimilar product for distribution and sale in assigned territories. - **Development collaboration partners** (secondary) — Fund and use partnered development programs tied to biosimilar candidates and milestones. - Pharma commercialization partners buying territorial rights - Licensees seeking biosimilar supply after product approval - Partners funding development in return for market exclusivity - Regional distributors and marketers of biosimilar brands - Collaborators needing regulatory and manufacturing support ## Geography Alvotech earns revenue across Europe, the USA, and Rest of World markets, with Europe the largest geography in the latest annual disclosure. The company’s operational footprint is international, with manufacturing and development rooted in Iceland and a commercialization model that relies on partners in multiple territories. Geography matters because out-license rights are tied to specific countries or regions, which shapes where product revenue and milestone income are recognized. - **Europe** (52.4%) — 2025 revenue from customers based on geographic market. - **USA** (41.1%) — 2025 revenue from customers based on geographic market. - **Rest of World** (6.4%) — 2025 revenue from customers based on geographic market. - Europe is the largest reported revenue region at 307,220 in 2025 - USA contributed 241,370 of revenue in 2025 - Rest of World contributed 37,731 of revenue in 2025 - Revenue follows territory rights under partner contracts - Manufacturing and core operations are anchored in Iceland ## Strategy Alvotech’s strategy centers on advancing a biosimilar pipeline, securing commercialization partners, and monetizing products through territory-specific out-licensing and supply agreements. The company also focuses on manufacturing and development capabilities that support multiple partnered launches across regions, which is essential in a business where scale and regulatory execution drive access to markets. - **Expand biosimilar pipeline and approvals** (medium-term) — Approved products and filed candidates are the basis for future partner launches and supply revenue. - **Deepen partner commercialization model** (short-term) — Third-party partners provide market access in territories where Alvotech does not sell directly. - **Scale manufacturing and supply reliability** (medium-term) — Biosimilar commercialization depends on consistent production quality and supply to partners. - Advance biosimilar candidates through preclinical and clinical stages - Use territory-based out-licensing to reach global markets - Support partner launches with commercial supply agreements - Build manufacturing capacity for complex biologic products - Secure financing and partner funding to support development ## Risks Alvotech faces the typical biotech risks of uncertain R&D outcomes, regulatory delays, and execution risk in manufacturing complex biologics. Its business model also depends heavily on third-party commercial partners and long-term financing, so any disruption in partner demand, launch timing, or funding access can materially affect operations. - **R&D and regulatory failure** [high] — Biosimilar candidates must prove comparability, safety, and efficacy before approval. - **Reliance on commercial partners** [high] — The company does not independently commercialize most products and depends on partners for market access. - **Customer concentration** [high] — A few customers account for a large share of annual revenue. - **Foreign exchange volatility** [medium] — Revenue, assets, liabilities, and financing span EUR, GBP, ISK, CHF, and USD. - Biosimilar programs may fail clinical or regulatory milestones - Revenue depends on commercial partners rather than direct sales - Manufacturing complexity can affect launch timing and supply - Foreign exchange movements affect a multi-currency business - Partner concentration creates customer-specific revenue volatility ## Accounting Revenue recognition is judgmental because the company uses shipment-based transfer of control for product sales and allocates consideration across license, development, and supply obligations in out-license contracts. Estimates for rebates, returns, chargebacks, and variable consideration can move reported revenue, while multi-currency operations, fair value measurements, and financing-related instruments can also create significant period-to-period volatility. - **Revenue recognition on shipment** — Quarterly revenue comparability - **Variable consideration estimates** — Net revenue and gross margin presentation - **Multi-element out-license accounting** — Timing and allocation of contract revenue - **Foreign currency translation** — Equity, finance income/costs, and volatility - Shipment-based revenue recognition affects timing of product sales - Variable consideration estimates affect net revenue - Out-license contracts require allocation across multiple obligations - Multi-currency balances create translation and remeasurement effects - Fair value estimates and financing instruments can affect finance income/costs --- *Last updated: 2026-09-28T10:46:39.105350+00:00*